BR112014005786A2 - antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares - Google Patents

antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares

Info

Publication number
BR112014005786A2
BR112014005786A2 BR112014005786A BR112014005786A BR112014005786A2 BR 112014005786 A2 BR112014005786 A2 BR 112014005786A2 BR 112014005786 A BR112014005786 A BR 112014005786A BR 112014005786 A BR112014005786 A BR 112014005786A BR 112014005786 A2 BR112014005786 A2 BR 112014005786A2
Authority
BR
Brazil
Prior art keywords
toll
metabolic
treatment
cardiovascular diseases
antagonists
Prior art date
Application number
BR112014005786A
Other languages
English (en)
Inventor
Teplyakov Alexey
Teng Fang
Luo Jinquan
Heeringa Katharine
San Mateo Lani
Wu Linda
Cunningham Mark
Rutz Mark
Sweet Raymond
Rauchenberger Robert
Sarisky Robert
Wu Sheng-Jiun
Stojanovic- Susulic Vedrana
Feng Yiqing
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112014005786A2 publication Critical patent/BR112014005786A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

abstract toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases toll like receptor 3 (tlr3) antibody antagonists, polynucleotides encoding tlr3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. ******************************************************** tradução do resumo resumo patente de invenção "antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares". a presente invenção refere-se a antagonistas de anticorpos do receptor tipo toll 3 (tlr3), polinucleotídeos que codificam os antagonistas de anticorpos tlr3 ou fragmentos dos mesmos, e a métodos para produzir e usar o supracitado.
BR112014005786A 2011-09-12 2011-09-12 antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares BR112014005786A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/051202 WO2013039471A1 (en) 2011-09-12 2011-09-12 Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases

Publications (1)

Publication Number Publication Date
BR112014005786A2 true BR112014005786A2 (pt) 2017-03-28

Family

ID=47883555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005786A BR112014005786A2 (pt) 2011-09-12 2011-09-12 antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares

Country Status (11)

Country Link
EP (1) EP2755685A4 (pt)
JP (1) JP2014526464A (pt)
KR (1) KR20140075708A (pt)
CN (1) CN104159610A (pt)
BR (1) BR112014005786A2 (pt)
CA (1) CA2855955A1 (pt)
EA (1) EA201490623A1 (pt)
IL (1) IL231413A0 (pt)
MX (1) MX362457B (pt)
NZ (1) NZ622260A (pt)
WO (1) WO2013039471A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370451B2 (en) * 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
WO2015016282A1 (ja) * 2013-07-30 2015-02-05 国立大学法人東京大学 放射線誘導性消化管症候群の予防又は治療用医薬組成物
EP4074730A1 (en) 2015-06-24 2022-10-19 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
CN101415438B (zh) * 2004-11-30 2013-03-27 森托科尔公司 Toll样受体3拮抗剂、方法和用途
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
US8895263B2 (en) * 2008-10-02 2014-11-25 Janssen Biotech, Inc. Methods for suppressing toll-like receptor activity
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
CN105601742A (zh) * 2008-10-31 2016-05-25 詹森生物科技公司 Toll样受体3拮抗剂
MX2011011623A (es) * 2009-04-29 2011-11-18 Janssen Biotech Inc Antagonistas del receptor tipo toll 3.

Also Published As

Publication number Publication date
CA2855955A1 (en) 2013-03-21
EP2755685A4 (en) 2015-07-01
MX2014002982A (es) 2015-07-06
IL231413A0 (en) 2014-04-30
EA201490623A1 (ru) 2016-01-29
WO2013039471A1 (en) 2013-03-21
JP2014526464A (ja) 2014-10-06
KR20140075708A (ko) 2014-06-19
NZ622260A (en) 2016-11-25
MX362457B (es) 2019-01-18
EP2755685A1 (en) 2014-07-23
CN104159610A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
CY1122278T1 (el) Αντι il-36r αντισωματα
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
CL2013003552A1 (es) Anticuerpo aislado que se une a la proteina 3 humana de tipo angiopoyetina (hangptl3); molécula de ácido nucleico; vector de expresión, célula hospedera; método de producción de un anticuerpo.
CL2015000431A1 (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
BR112014010439A2 (pt) compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015006060A2 (pt) agentes de ligação kir3dl2
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
UA116766C2 (uk) Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112014026703A2 (pt) inibidores de dna-pk
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
BR112014015111A2 (pt) composições e processos para anticorpos que se direcionam ao fator p
EA201400969A1 (ru) Новые терапевтические подходы для лечения болезни паркинсона
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112014027303A2 (pt) identificação de variantes de isopreno sintase com propriedades optimizadas para a produção de isopreno
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2532 DE 16/07/2019 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL